Background 23
Introduction 45
Nontypeable Haemophilus influenzae (NTHi) is a common coloniser of the human 46 nasopharynx [1], and frequently causes respiratory tract infections, including otitis media 47 and sinusitis [2] . Occasionally, NTHi can cause serious invasive infections, including 48 septicaemia and meningitis, particularly in individuals with underlying co-morbidities, and 49 is associated with significant case-fatality [3, 4] . However, the main burden of disease 50
with NTHi is pneumonia [5] and although data on the aetiology of non-bacteraemic 51 pneumonia are limited, numerous studies have identified NTHi in lung aspirates and 52 sputum of patients with pneumonia [6, 7] . Depending on geographical area, NTHi is 53 either the second [8] or third [9] most common cause of community acquired pneumonia 54
after Streptococcus pneumoniae and Mycoplasma pneumoniae. NTHi disease is most 55 frequently associated with viral infection [10] presenting as secondary or superinfections 56 which increase disease severity and lead to increased mortality [11] . 57 58 NTHi also plays a major role in exacerbations of chronic respiratory conditions, including 59 chronic suppurative lung disease (CSLD) and bronchiectasis in children [12, 13] and 60 chronic obstructive pulmonary disease (COPD) in the elderly [14] . Treatments that 61 reduce the load of bacteria, including NTHi, can improve symptoms and reduce long-62 term lung damage [15] . However, in the absence of a licensed vaccine for NTHi [16] , this 63 is currently only possible through undesirable, prolonged multiple courses of broad-64 spectrum antibiotics, which are associated with significant adverse effects, including the 65 development of antibiotic resistance [17] . 66
67
The recently licensed 10-valent pneumococcal conjugate vaccine (Synflorix, GSK 68 Biologicals) (PHiD-CV) uses H. influenzae Protein D as its carrier protein for 8 of the 10 69 pneumococcal serotypes and therefore offers a potential advantage in that it might also prevent NTHi infections. NTHi pneumonia is the most severe manifestation of the 71 respiratory tract infection spectrum of NTHi and much more common than invasive 72
NTHi, therefore prevention of NTHi pneumonia should be a key goal of any NTHi 73 vaccine. The difficulties in identifying the aetiology of non-bacteraemic pneumonia in 74 patients mean that animal modelling is useful in determining vaccine efficacy against 75
NTHi lung infection. If PHiD-CV was efficacious against NTHi pneumonia, it could 76 protect millions of children and would also become an attractive alternative to the 77 pneumococcal polysaccharide vaccine (Pneumovax 23, Merck Vaccines) (PPV23). 78 PPV23 is routinely offered to older adults (≥65year olds) and high-risk individuals in 79 many countries, despite having limited protective efficacy [18] . An NTHi vaccine may 80 also benefit older adults, who are at increased risk of NTHi infections, through 81 establishing herd immunity, as observed following the introduction of the Haemophilus 82 influenzae B (HiB) vaccine [19] . 83 84 Protein D is a highly-conserved, surface-exposed 42 kDa outer membrane lipoprotein 85 found in all H. influenzae strains, making it a promising vaccine candidate antigen [20] . to Protein D [22, 23] and the 11-valent precursor vaccine was estimated to prevent 35% 94 of NTHi acute otitis media episodes [24] . 95
The aim of the current study was to determine whether the Protein D in PHiD-CV can 97 protect against NTHi lung infection. To test this, we developed two mouse models of 98
NTHi lung infection (with and without prior influenza infection). We immunized mice with 99
PHiD-CV, PCV13 (which does not contain Protein D) or heat-killed (HK) NTHi, and 100 subsequently infected with NTHi alone or with H1N1 influenza virus followed by NTHi. 101
We observed high levels of antibody against Protein D in mice immunized with PHiD-CV, 102 but did not increase clearance of pulmonary NTHi. or PBS. This volume is 1/10 th of the human dose. A boost immunization was performed 132 at day 21. For infections, mice were anesthetized using isoflurane and infected 133 intranasally (i.n.) with 10 7 CFU of log phase NTHi 162 in a volume of 100 μL 5% BHI in 134 PBS (used to maximize viability of NTHi). For superinfection experiments, mice were first 135 infected with 5 x 10 4 or 10 5 PFU of influenza A H1N1 followed 7 days later by 10 5 or 10 7 136 CFU of log phase NTHi 162. Mock infection was performed using 5% BHI in PBS or PBS 137 alone. 138
Materials and Methods

139
Tissue and cell recovery and isolation 140
Mice were culled using 100 μL intraperitoneal pentobarbitone (20 mg dose, Pentoject, 141
Animalcare Ltd. UK) and tissues collected. Blood was collected from carotid vessels and 142 sera isolated after clotting by centrifugation. Bronchoalveolar lavage (BAL) was obtained 143 by inflating the lungs via an intratracheal cannula with 5% BHI in PBS. Lungs were 144 removed and homogenized by passage through 100 μm cell strainers and centrifugation 145
at 200 x g for 5 minutes. Aliquots were removed and serially diluted for bacterial 146 enumeration and the remainder treated with red blood cell lysis buffer (ACK; 0.15 M 147 ammonium chloride, 1 M potassium hydrogen carbonate, and 0.01 mM EDTA, pH 7.2) 148 before centrifugation at 200 x g for 5 minutes. The remaining cells were resuspended in 149 RPMI 1640 medium with 10% fetal calf serum and viable cell numbers determined by 150 trypan blue exclusion. For differential cell counts, 100 μL of cells from BAL and the lung 151 homogenate were centrifuged onto glass slides. Samples were air dried, and fixed in 152 methanol, before staining of with haematoxylin and eosin. 
Statistical Analysis 170
Comparisons of two groups were performed using Student's t tests. Comparisons of 171 multiple groups were performed using one-or two-way ANOVA with appropriate post-172 tests. All statistical tests were performed using GraphPad Prism version 6.01 for 173
Windows (GraphPad Software, San Diego California USA).
Results 175
Characterization of NTHi infection 176
BALB/c mice were intranasally infected with 10 7 CFU of NTHi strain 162 in 100 μL. 177
Weight loss was apparent after 24 hours and infected mice showed a significant 178 reduction in weight compared to controls up to 72 hours after infection (p<0.01, Fig.1A) . 179
At two hours after infection, a bacterial load of ~5 x10 6 CFU was recoverable from both 180 the BAL and lungs ( Fig.1B and C) . After 24 hours, the concentration of viable bacteria 181 had fallen ~100-fold in the BAL and ~50-fold in the lungs. By 48 hours, ~5 x 10 2 CFU 182 were remaining in both the BAL and lungs, no viable NTHi were detected by 72 hours. 183
Airway cellular infiltration was observed after 24 hours and peaked at 48 hours (p<0.001, 184 infiltration occurred more rapidly and persisted for longer than in BAL, with a significant 186 increase in cell counts from 2 hours which was maintained for the entire time course of 187 72 hours (p<0.001, Fig.1E ). Differential cell counts from BAL identified a prominent 188 airway neutrophilia, though increases in lymphocytes and macrophages were also 189 observed ( Fig.1F ). In addition to the cellular markers of inflammation the pro-190 inflammatory cytokine interleukin-6 (IL-6) ( Fig.1G ) and the neutrophil chemoattractant CFU NTHi. To screen for augmented clearance we measured NTHi in BAL at 24 and 48 210 hours after infection. No difference was seen between the immunized, control 211 immunized and non-immunized groups (Fig.3A) . We wished to determine whether there 212 was an effect on disease rather than only bacterial clearance and so focussed on 48 213 hours after infection, the peak of weight loss and cellular infiltration. 48 hours after 214 infection, lower bacterial loads were observed for all the immunized groups compared to 215 the non-immunized control group in the BAL (p<0.05, Fig.3B ) and in the lung (p<0.001, 216
Fig.3C), but there was no significant difference between the PHiD-CV and the PCV13 or 217
HK-NTHi immunized groups. In the lung, both the PCV13 and HK-NTHi groups had a 218 lower bacterial load than the non-immunized groups. However, these changes in 219 bacterial load did not lead to a significant change in disease outcome. There was no 220 significant difference in weight loss between the infected groups at either 24 or 48 hours 221 after infection ( Fig.3D ). Cellular infiltration in the BAL was similar for all infected groups 222 
Immunization fails to protect against NTHi superinfection 253
A superinfection protocol using 5 x 10 4 PFU influenza and 10 5 CFU NTHi was selected 254 for assessment of protection by PHiD-CV. These doses were chosen as they model a 255 typical opportunistic NTHi infection in which immunity must be compromised to establish 256 disease, and, importantly, use a low dose for bacterial infection. No significant 257 differences in weight change after NTHi-infection were observed between the differently 258 immunized groups (Fig.5A ). Airway bacterial loads ( Fig.5B and C) and cell infiltration 259 
Discussion 263
This study aimed to determine whether immunization with PHiD-CV cross-protects 264 against NTHi lung infection. While immunization with PHiD-CV induced high levels of 265
Protein D specific antibodies, the small reduction in bacterial load in the airways and 266 lungs was not sufficient to affect disease outcome. Furthermore, the reduced bacterial 267 load compared to PBS-immunized mice must be interpreted with caution, because the 268 bacterial load in the PHiD-CV immunized mice was not significantly different to 269 immunization with PCV13, which contains no NTHi antigens. PHiD-CV immunization did 270 not protect against disease or reduce bacterial load in the influenza A-NTHi 271 superinfection model. One limitation is that we only tested one dose regime of the 272 vaccine (1/10 th human dose), other doses may have had different efficacy, though the 273 dose used is a larger bolus of vaccine per muscle mass than used in humans. Only one 274 strain of NTHi was tested in this study, 162, and it may be that PHiD-CV is protective 275 against other strains, The significant strain heterogeneity is exactly the rationale for 276 assessing PD as a vaccine candidate, as it is highly conserved across NTHi. Therefore, 277
if an effect was observed it would be theoretically be expected for the majority of NTHi 278 strains. NTHi strain 162 is an upper respiratory tract pathogen isolated from a child in 279
Finland [25] , it was chosen on account of good growth in media and virulence in mice 280 upon i.n. infection into the lung in our preliminary studies and virulence in other models 281 Alternatively, antibodies raised by Protein D in PHiD-CV may not be specific for surface-315 exposed Protein D epitopes on whole NTHi. Though Protein D is a surface exposed 316 protein, it is highly conserved among H. influenzae suggesting that it is under little 317 immune pressure [40] . The lack of protection observed may be influenced by the against Protein D. There are limits translating these findings from the mouse model to humans, but, in combination with the lack of a clear protective effect against carriage in 367 recent clinical trials, we believe that PHiD-CV is unlikely to offer any additional benefit 368 against NTHi pneumonia. 369
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